20.00GBp+5.26%Mkt Cap: 217.93M GBpP/E: —Last update: 2026-05-13
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phas…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-21.06
PEG—
P/B-28.44
P/S50.12
EV/EBITDA-18.80
EV/Revenue51.73
EPS (TTM)-0.01
EPS (Forward)-0.01
Cash Flow & Leverage
FCF Yield-7.85%
FCF Margin-363.38%
Operating CF-6.40M GBp
CapEx (TTM)1.54M GBp
Net Debt/EBITDA-0.59
Net Debt7.61M GBp
Technical
SMA 5013.62 (+46.8%)
SMA 20011.42 (+75.2%)
Beta0.57
S&P 52W Chg24.23%
Avg Vol (30d)1.87M
Avg Vol (10d)2.71M
Technical Indicators
RSI (14)86.2
MACD1.5228
MACD Signal0.9115
MACD Hist.+0.6113
BB Upper18.89 GBp
BB Middle14.60 GBp
BB Lower10.31 GBp
BB Width58.78%
ATR (14)1.191 GBp
Vol Ratio (20d)2.05x
52W Range
7.85686% of range22.00
52W High22.00 GBp
52W Low7.856 GBp
Profitability
Gross Margin94.95%
EBITDA Margin-275.17%
Profit Margin-260.50%
Oper. Margin-283.34%
ROE320.00%
ROA-53.15%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-4.24
Current Ratio0.56
Quick Ratio0.56
Book Value/Sh-0.0080 GBp
Cash/Share0.0080 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split10:1
Split DateJul 26, 2011
Ownership
Shares Out.1.04B
Float582.70M
Insiders3.65%
Institutions44.64%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)31.00 GBp
Target Range30.00 GBp – 32.00 GBp
# Analysts2
Company
Market Cap217.93M GBp
Enterprise Value243.70M GBp
Revenue (TTM)4.71M GBp
Gross Profit4.47M GBp
Net Income (TTM)-12.27M GBp
Revenue/Share0.0050 GBp
Fiscal Year EndApr 2025
MR QuarterOct 2025
Employees60
Last Price20.00 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—